These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 35923949)

  • 1. Degarelix vs. leuprorelin for the treatment of prostate cancer in China: A cost-utility analysis.
    Yan J; Li C; Zhang X; Cheng L; Ding R; Zhang L
    Front Public Health; 2022; 10():942800. PubMed ID: 35923949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A cost-utility analysis of degarelix in the treatment of advanced hormone-dependent prostate cancer in the United Kingdom.
    Lee D; Porter J; Gladwell D; Brereton N; Nielsen SK
    J Med Econ; 2014 Apr; 17(4):233-47. PubMed ID: 24568188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of degarelix for advanced hormone-dependent prostate cancer.
    Lu L; Peters J; Roome C; Stein K
    BJU Int; 2012 Apr; 109(8):1183-92. PubMed ID: 21883830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cost effectiveness of GnRH antagonists in patients with prostate cancer and cardiovascular risk : Comparative analysis against Leuprorelin by the Number Needed to Treat].
    Anderson D; Lehmann J; Ecker T; Vosgerau S; Donatz V
    Urologe A; 2017 Jul; 56(7):917-924. PubMed ID: 28405705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Degarelix for Treating Advanced Hormone-Dependent Prostate Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Uttley L; Whyte S; Gomersall T; Ren S; Wong R; Chambers D; Tappenden P
    Pharmacoeconomics; 2017 Jul; 35(7):717-726. PubMed ID: 27943135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost utility of tumour necrosis factor-α inhibitors for rheumatoid arthritis: an application of Bayesian methods for evidence synthesis in a Markov model.
    Nguyen CM; Bounthavong M; Mendes MA; Christopher ML; Tran JN; Kazerooni R; Morreale AP
    Pharmacoeconomics; 2012 Jul; 30(7):575-93. PubMed ID: 22640174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China.
    Wu B; Chen H; Shen J; Ye M
    Clin Ther; 2011 Oct; 33(10):1446-55. PubMed ID: 21992806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality of life improvement in patients treated with degarelix versus leuprorelin for advanced prostate cancer.
    Lee D; Nielsen SK; van Keep M; Andersson F; Greene D
    J Urol; 2015 Mar; 193(3):839-46. PubMed ID: 25264336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of Osimertinib vs Docetaxel-bevacizumab in Third-line Treatment in EGFR T790M Resistance Mutation Advanced Non-Small Cell Lung Cancer in China.
    Rui M; Li H
    Clin Ther; 2020 Nov; 42(11):2159-2170.e6. PubMed ID: 33028495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of Pembrolizumab in Combination with Chemotherapy as Neoadjuvant Treatment and Continued as a Single Agent Adjuvant Treatment for High-Risk Early-Stage Triple-Negative Breast Cancer in Hong Kong.
    Kwong A; Leung R; Chan TC; Khandelwal A; Mishra K; Huang M
    Oncol Ther; 2024 Sep; 12(3):525-547. PubMed ID: 39037537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of Abiraterone Acetate versus Docetaxel in the management of metastatic castration-sensitive prostate cancer: Hong Kong's perspective.
    Chiang CL; So TH; Lam TC; Choi HCW
    Prostate Cancer Prostatic Dis; 2020 Mar; 23(1):108-115. PubMed ID: 31273290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness Analysis of Anlotinib as Third- or Further-Line Treatment for Relapsed Small Cell Lung Cancer (SCLC) in China.
    Gong J; Wan Q; Shang J; Qian X; Su D; Sun Z; Liu G
    Adv Ther; 2021 Oct; 38(10):5116-5126. PubMed ID: 34417989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted therapies and conventional care for the treatment of ankylosing spondylitis in China: a cost-effectiveness analysis based on the network-meta analysis.
    Shi J; Zhou W; Lin T; Wu F; Hu M
    J Orthop Surg Res; 2024 Aug; 19(1):491. PubMed ID: 39155381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness and Value-based Pricing of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Low HER2 Expression.
    Huang X; Lin D; Lin S; Luo S; Huang X; Deng Y; Weng X; Huang P
    Clin Breast Cancer; 2023 Jul; 23(5):508-518. PubMed ID: 37085377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of empagliflozin as a treatment for heart failure with reduced ejection fraction: an analysis from the Chinese healthcare perspective.
    Lin X; Lin M; Liu M; Huang W; Nie X; Chen Z; Zheng B
    J Thorac Dis; 2022 May; 14(5):1588-1597. PubMed ID: 35693603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness of Tislelizumab Versus Docetaxel for Previously Treated Advanced Non-Small-Cell Lung Cancer in China.
    Gong J; Su D; Shang J; Xu S; Tang L; Sun Z; Liu G
    Front Pharmacol; 2022; 13():830380. PubMed ID: 35614942
    [No Abstract]   [Full Text] [Related]  

  • 17. Cost-Effectiveness Analysis of Corneal Collagen Crosslinking for Progressive Keratoconus.
    Godefrooij DA; Mangen MJ; Chan E; O'Brart DPS; Imhof SM; de Wit GA; Wisse RPL
    Ophthalmology; 2017 Oct; 124(10):1485-1495. PubMed ID: 28532974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of adding transarterial chemoembolisation to lenvatinib as first-line treatment for advanced hepatocellular carcinoma in China.
    Li W; Wan L
    BMJ Open; 2023 Sep; 13(9):e074245. PubMed ID: 37751954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of a population-based AAA screening program for men over 65 years old in Iran.
    Daroudi R; Shafe O; Moosavi J; Salimi J; Bayazidi Y; Zafarghandi MR; Maleki M; Moini M; Farshidmehr P; Sadeghipour P
    Cost Eff Resour Alloc; 2021 May; 19(1):29. PubMed ID: 33985531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-Effectiveness Analysis of the TCM "Yupingfeng Granules" in the Treatment of Acute Exacerbations of COPD Based on a Randomized Clinical Trial.
    Hu M; Ding P; Ma J; Yang N; Zheng J; Zhou N
    Int J Chron Obstruct Pulmon Dis; 2022; 17():2369-2379. PubMed ID: 36176739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.